Healthcare Claims Audit Companies for Infectious Disease Practices

The appropriate ICD-10-CM code depends on the documented influenza type and the pneumonia relationship described in the clinical record. Influenza with pneumonia may require a combination of influenza and pneumonia coding based on the identified virus and current coding guidance. Review the provider’s documentation, code-set year, payer requirements, and official ICD-10-CM instructions before submitting a claim.

Influenza B pneumonia coding depends on the specific influenza B diagnosis documented and whether the record supports pneumonia as an associated complication. The correct code may vary by the code-set year and documentation detail. Coders should verify the current ICD-10-CM tabular instructions, confirm the clinical wording, and avoid selecting a code based only on a test result without the required provider documentation.

An audit may examine charge capture, documentation, coding, claim submission, payer payments, denials, authorization, drug and administration billing, A/R follow-up, and contract compliance. For infectious disease practices, the review can also consider office visits, hospital consults, infusion services, OPAT, specialty drugs, and buy-and-bill activity. The purpose is to trace revenue gaps to their operational or documentation source.

Common causes include missing authorization, medical-versus-pharmacy benefit confusion, drug or administration coding issues, under-documented consults, unit or NDC mismatches, and payer-specific claim requirements. Reviewing denials by root cause helps distinguish isolated errors from recurring workflow problems. Findings can then be shared with clinical, coding, front-office, and billing teams to reduce repeat issues.

Yes. Payment reconciliation compares payer payments with expected reimbursement for drug, administration, and E/M claims. The review can flag short-pays, incorrect fee schedule application, unit discrepancies, NDC mismatches, and other payment variances. Identified underpayments can be disputed and tracked, while the results may also reveal contract or billing workflow issues that need broader attention.

A review can cover the workflow from referral to final payment, including documentation, coding, eligibility, prior authorization, drug acquisition, infusion billing, denial management, A/R follow-up, and payer or hospital coverage agreements. Practices may use the assessment when launching an infusion suite or OPAT program, adding providers, or addressing a revenue cycle that has outgrown existing processes.

A/R follow-up can organize outstanding claims by payer, service type, and balance, with particular attention to high-value drug, infusion, hospital consult, and complex outpatient claims. Each follow-up action should be documented through resolution. Reviewing why claims stalled can identify recurring authorization, coding, submission, payment, or payer-response patterns that require process changes.

Yes. GrowInfectiousDisease is designed to help practices apply their own numbers rather than rely on generalized rates, costs, payment assumptions, or margin figures. Its browser-based tools and explainers support evaluation of revenue streams, operational choices, and financial sustainability. The resource also distinguishes verified information from unknown or practice-specific figures and does not publish invented benchmarks.